RAMSEY, N.J.--(EON: Enhanced Online News)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions will be approximately $26.5 million.
Oppenheimer & Co. acted as sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc., Maxim Group LLC and Laidlaw & Company (UK) Ltd. acted as co-managers.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (SEC) on October 16, 2013. Copies of the final prospectus relating to the offering may be obtained from Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com. An electronic copy of the final prospectus relating to the offering is also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ADMA Biologics, Inc.
ADMA is a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-compromised for medical reasons. ADMA also operates ADMA Bio Centers, an FDA-licensed and GHA-certified source plasma collection facility located in Norcross, Georgia, which provides ADMA with a portion of its blood plasma for the manufacture of its lead product candidate.